Abbott Laboratories (NYSE:ABT) Receives $147.00 Consensus PT from Analysts

Shares of Abbott Laboratories (NYSE:ABT) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $147.00.

A number of research analysts have issued reports on the stock. Mizuho upped their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, October 14th. Benchmark started coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 price objective on the stock. Barclays raised their target price on Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. BTIG Research reiterated a “buy” rating and set a $145.00 price target on shares of Abbott Laboratories in a research note on Thursday, November 20th. Finally, Raymond James Financial increased their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the last quarter. Cloud Capital Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC boosted its position in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $124.15 on Tuesday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a fifty day moving average price of $125.99 and a 200-day moving average price of $129.61. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The firm has a market cap of $215.88 billion, a PE ratio of 15.56, a P/E/G ratio of 2.06 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the company earned $1.21 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.